Sugi Predict

Sugi Predict / Compounds / SCHEMBL678403

SCHEMBL678403

SCHEMBL678403

CCOP(=O)(OCC)C(=Cc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)P(=O)(OCC)OCC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HMGCR P04035 4/20 1.00
▸ NR1I2 O75469 3/20 1.00
▸ LMNA P02545 3/20 0.45
▸ RECQL P46063 3/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ CYP3A4 P08684 3/20 0.45
▸ MAPT P10636 3/20 0.45
▸ TSHR P16473 3/20 0.45
▸ BLM P54132 3/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ HSD17B10 Q99714 3/20 0.45
▸ CYP1A2 P05177 3/20 0.45
▸ CYP2C9 P11712 3/20 0.45
▸ RGS12 O14924 2/20 0.45
▸ GMNN O75496 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ TP53 P04637 2/20 0.45
▸ HPGD P15428 2/20 0.45
▸ ALOX15 P16050 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7134494 0.92 HMGCR (0.85) HMGCRNR1I2LMNARECQLMEN1
SCHEMBL7083282 0.91 HMGCR (0.83) HMGCRNR1I2LMNARECQLMEN1
SCHEMBL7137096 0.91 HMGCR (0.83) HMGCRNR1I2LMNARECQLMEN1
SCHEMBL7521931 0.89 HMGCR (0.80) HMGCRNR1I2LMNARECQLMEN1
SCHEMBL12160467 0.87 HMGCR (0.77) HMGCRNR1I2LMNARECQLMEN1
SCHEMBL7083307 0.86 HMGCR (0.76) HMGCRNR1I2LMNARECQLMEN1
SCHEMBL7078823 0.86 HMGCR (0.75) HMGCRNR1I2LMNARECQLMEN1
SCHEMBL7522654 0.83 HMGCR (0.71) HMGCRNR1I2LMNARECQLCYP1A2
SCHEMBL7141651 0.83 HMGCR (0.71) HMGCRNR1I2LMNARECQLMEN1
SCHEMBL17407580 0.82 HMGCR (0.70) HMGCRNR1I2LMNARECQLMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118267480-A Application of PXR agonist and fecal bacterium transplantation combined treatment in colonitis field 郑州大学第二附属医院 2024-07-02 — — CN claimed
WO-2023106273-A1 VIRAL GROWTH INHIBITOR 慶應義塾 2023-06-15 — — WO claimed
US-20100166917-A1 Preservative System For Acidic Beverages Based On Sequestrants PEPSICO, INC. (US) 2010-07-01 — — US claimed
EP-1326618-A2 USE OF ARYL-SUBSTITUTED 1,1-DIPHOSPHONATES FOR THE TREATMENT OF BONE DISEASES Ilex Oncology Research S.A. (CH) 2003-07-16 — — EP claimed
WO-2002011704-A2 USE OF ARYL-SUBSTITUTED 1,1-DIPHOSPHONATES FOR THE TREATMENT OF BONE DISEASES SYMPHAR S.A. (CH) 2002-02-14 — — WO claimed
EP-0845991-B1 USE OF PHENOL SUBSTITUTED DIPHOSPHONATES AS ANTINEOPLASTIC AGENTS SYMPHAR SA (CH) 2002-02-06 — — EP claimed
EP-0339237-B1 PHENOL SUBSTITUTED GEM-DIPHOSPHONATE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SYMPHAR S.A. (CH) 1992-12-30 — — EP claimed
US-5128331-A Gen-diphosphonates SYMPHAR S.A. (CH) 1992-07-07 — — US claimed
US-12583848-B2 Isoxazole-3-carboxamide derivatives and their use for treatment of diseases caused by virus infection COLLABORATIONS PHARMACEUTICALS, INC. 2026-03-24 — — US disclosed
US-12533309-B2 Minoxidil adjuvant therapies CARING BRANDS, INC. (US) 2026-01-27 — — US disclosed
US-12527729-B2 Minoxidil adjuvant therapies CARING BRANDS, INC. (US) 2026-01-20 — — US disclosed
EP-4659812-A1 DETECTION METHODS AND COMBINATION THERAPIES OF CELLS WITH EXTRACELLULAR RAS EXPRESSION Bumm, Thomas (DE) 2025-12-10 — — EP disclosed
US-20250360128-A1 MINOXIDIL ADJUVANT THERAPIES JUPITER WELLNESS INC (US) 2025-11-27 — — US disclosed
EP-4536354-A1 MINOXIDIL ADJUVANT THERAPIES Jupiter Wellness, Inc. (US) 2025-04-16 — — EP disclosed
US-20060003975-A1 Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor PHARMACIA CORPORATION 2006-01-05 — — US disclosed
CN-1537019-A Medical combination of aldosterone receptor antagonist and HMG CoA reductase inhibitor �ź㴫 2004-10-13 — — CN disclosed
EP-1326618-A2 USE OF ARYL-SUBSTITUTED 1,1-DIPHOSPHONATES FOR THE TREATMENT OF BONE DISEASES Ilex Oncology Research S.A. (CH) 2003-07-16 — — EP disclosed
WO-2002011704-A2 USE OF ARYL-SUBSTITUTED 1,1-DIPHOSPHONATES FOR THE TREATMENT OF BONE DISEASES SYMPHAR S.A. (CH) 2002-02-14 — — WO disclosed
US-5128331-A Gen-diphosphonates SYMPHAR S.A. (CH) 1992-07-07 — — US disclosed
US-5043330-A Antiinflammatory and hypotensive agents; antihyperlipemia SYMPHAR S.A. (CH) 1991-08-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12527729-B2 Minoxidil adjuvant therapies RXRA, RXRB, RXRG HMGCR 1134/4885NR1I2 32/4885LMNA 3347/4885
US-20060003975-A1 Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor HMGCR, NR3C2, LDLR HMGCR 1/4885NR1I2 77/4885LMNA 964/4885
US-12533309-B2 Minoxidil adjuvant therapies RXRG, RXRA, RXRB HMGCR 579/4885NR1I2 44/4885LMNA 4441/4885
US-12583848-B2 Isoxazole-3-carboxamide derivatives and their use for treatment of diseases caused by virus infection CYP3A43, COX4I1, CYP3A4 HMGCR 875/4885NR1I2 77/4885LMNA 1727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.